Although the FLYER trial demonstrated non‐inferiority of four cycles of CHOP with six doses of rituximab compared to six cycles of R‐CHOP in young patients with aggressive B‐cell lymphoma, its findings are not directly applicable to older patients (> 60 years) or those with extranodal disease. Here, DDIT3 is linked to B-cell non-Hodgkin lymphoma.